[e-drug] Overriding drug and medical technology patents for pandemic recovery: a legitimate move for high-income countries too.

e-drug
1

E-DRUG: Overriding drug and medical technology patents for pandemic recovery: a legitimate move for high-income countries too.
---------------------------------------------------------------------------

Katrina Perehudoff
Ellen'tHoen
Pascale Boulet

BMJ Global Health 2021;6:e005518.

http://dx.doi.org/10.1136/bmjgh-2021-005518

Summary
- Compulsory licenses are legal tools to override patent-protection on
   medicines and medical technologies.

- Compulsory licenses can help scale up the production and lower prices of patent-protected medicines while still accounting for the patent holder's interests.

- Compulsory licensing is making a comeback in high-income countries as a negotiation strategy and a legal tool to remedy high prices and/or supply shortages of medicines and medical technologies.
   
- High-income countries that face potential legal hurdles (in world trade law and/or in the regulation of test data and market exclusivity) to effectively use compulsory licensing in the COVID-19 pandemic should consider taking measures now

Katrina Perehudoff PhD

Post Doctoral Research Fellow in European and Global Health
Faculty of Law, University of Amsterdam, Netherlands
Post Doctoral Assistant Department of Public Health &
Primary Care, Ghent University, Belgium

Affiliated with:
Amsterdam Centre for European Law & Governance at the University of
Amsterdam, Amsterdam Institute for Global Health & Development

WHO Collaborating Centre for Governance, Accountability, and Transparency
in the Pharmaceutical Sector at the University of Toronto
Katrina Perehudoff <katrina.perehudoff@gmail.com>

2

Из E-DRUG: Overriding drug and medical technology patents for pandemic
recovery: a legitimate move for high-income countries too.
---------------------------------------------------------------------------
Отмена патентов на лекарства и медицинские технологии для борьбы с пандемией: законный шаг и для стран с высоким уровнем доходов. Перевод: Гугл

Katrina Perehudoff
Ellen'tHoen
Pascale Boulet

BMJ Global Health 2021;6:e005518. http://dx.doi.org/10.1136/bmjgh-2021-005518

Резюме
  - Принудительные лицензии - это правовые инструменты, отменяющие патентную защиту на
    лекарства и медицинские технологии.

- Принудительные лицензии могут помочь увеличить производство и снизить цены на
защищенные патентом лекарства, при этом все еще составляя долю интереса патентообладателя.

- Принудительное / Обязательное лицензирование возвращается в страны с высоким уровнем доходв как стратегия переговоров и правовой инструмент для устранения высоких цен и / или поставок при нехватке лекарств и медицинских технологий.

- Странам с высоким уровнем дохода, сталкивающимся с потенциальными юридическими препятствиями (в мировой торговле закон и / или в регулировании тестовых данных и исключительности рынка), чтобы эффективно использовать принудительное лицензирование в условиях пандемии COVID-19 следует подумать о принятии мер сейчас.

Summary
- Compulsory licenses are legal tools to override patent-protection on
   medicines and medical technologies.

- Compulsory licenses can help scale up the production and lower prices of
patent-protected medicines while still accounting for the patent holder's
interests.

- Compulsory licensing is making a comeback in high-income countries as a
negotiation strategy and a legal tool to remedy high prices and/or supply
shortages of medicines and medical technologies.

- High-income countries that face potential legal hurdles (in world trade
law and/or in the regulation of test data and market exclusivity) to
effectively use compulsory licensing in the COVID-19 pandemic should
consider taking measures now

Katrina Perehudoff PhD

Post Doctoral Research Fellow in European and Global Health
Faculty of Law, University of Amsterdam, Netherlands
Post Doctoral Assistant Department of Public Health &
Primary Care, Ghent University, Belgium

Affiliated with:
Amsterdam Centre for European Law & Governance at the University of
Amsterdam, Amsterdam Institute for Global Health & Development

WHO Collaborating Centre for Governance, Accountability, and Transparency
in the Pharmaceutical Sector at the University of Toronto
Katrina Perehudoff <katrina.perehudoff@gmail.com>